StreetAlpha
13F holdings · Q3 2026

Decheng Capital

Menlo Park, CA · files as Decheng Capital LLC
Know the moment Decheng Capital filesYou follow Decheng Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2010850

Decheng Capital reported 11 stocks worth $685M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are CGON (65.9%), NUVB (21.2%) and ACRS (3.1%). Compared with Q2 2026, the fund trimmed RCUS and BYSI and sold out of RVMD, NAMS and TNGX.

Latest filing: what Decheng Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new0 added2 trimmed3 sold outBought about $0 · sold about $18.1M
New 0

None

Added 0

None

Trimmed 2
Sold out 3

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$685M−6.4% vs last quarter
Stocks held110 new · 3 sold out
Top 5 weight95.4%very concentrated
Turnover3%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
CGON
CG Oncology Inc
$452M65.9%6.4MNo change8 of 8
2
NUVB
Nuvation Bio Inc
$145M21.2%26MNo change8 of 8
3
ACRS
Aclaris Therapeutics Inc
$21.3M3.1%4MNo change8 of 8
4
AARD
Aardvark Therapeutics Inc
$20.6M3.0%3.9MNo change7 of 8
5
UPB
Upstream Bio Inc
$14.4M2.1%2.7MNo change8 of 8
6
RCUS
Arcus Biosciences Inc
$11M1.6%425K−40K (−9%)8 of 8
7
EQ
Equillium Inc
$7.2M1.1%4.4MNo change8 of 8
8
LYEL
Lyell Immunopharma, Inc.
$6.8M1.0%692KNo change8 of 8
9
ZNTL
Zentalis Pharmaceuticals Inc
$3.7M0.5%1.3MNo change8 of 8
10
BYSI
Beyondspring Inc
$2.4M0.3%3.1M−735K (−19%)8 of 8
🔒 1 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
RVMD
Revolution Medicines Inc
$9.9M53K
NAMS
Newamsterdam Pharma Company
$6M177K
TNGX
Tango Therapeutics Inc
$625K20K

Reported value

last 8 quarters
$466MQ4 '24
$356MQ1 '25
$396MQ2 '25
$573MQ3 '25
$743MQ4 '25
$661MQ1 '26
$732MQ2 '26
$685MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Decheng Capital 13F FAQ

What does Decheng Capital own?

Decheng Capital reported 11 stocks worth $685M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are CGON (65.9%), NUVB (21.2%) and ACRS (3.1%). The table above lists every position in the filing (the top 10 without an account).

What did Decheng Capital buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 0 added to, 2 trimmed and 3 sold out. It sold all of RVMD, NAMS and TNGX.

When will Decheng Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Decheng Capital's portfolio worth?

The Q3 2026 filing reports $685M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.